Savara Inc. (NASDAQ:SVRA - Get Free Report)'s share price gapped up before the market opened on Wednesday. The stock had previously closed at $4.48, but opened at $4.65. Savara shares last traded at $4.8220, with a volume of 927,384 shares changing hands.
Analyst Ratings Changes
Several equities analysts have weighed in on the company. Royal Bank Of Canada set a $10.00 target price on Savara in a research report on Wednesday, October 7th. Wall Street Zen cut shares of Savara from a "hold" rating to a "sell" rating in a research report on Sunday, October 4th. HC Wainwright started coverage on shares of Savara in a research report on Thursday, November 12th. They set a "buy" rating and a $10.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Savara in a research note on Wednesday, October 7th. They issued an "overweight" rating and a $12.00 price objective for the company. Finally, Citigroup restated a "market outperform" rating on shares of Savara in a report on Wednesday, October 7th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $10.29.
Get Our Latest Research Report on Savara
Savara Stock Performance
The stock has a market capitalization of $1.05 billion, a PE ratio of -7.83 and a beta of 0.32. The stock has a fifty day moving average of $4.90 and a 200-day moving average of $5.33. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.28.
Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. Equities analysts anticipate that Savara Inc. will post -0.68 earnings per share for the current fiscal year.
Institutional Trading of Savara
A number of large investors have recently made changes to their positions in the company. Renaissance Technologies LLC raised its stake in Savara by 96.5% in the first quarter. Renaissance Technologies LLC now owns 652,672 shares of the company's stock valued at $3,564,000 after buying an additional 320,572 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Savara during the 2nd quarter worth about $1,532,000. Nantahala Capital Management LLC acquired a new position in shares of Savara during the 2nd quarter worth about $42,977,150. BlackRock Inc. acquired a new position in shares of Savara during the 2nd quarter worth about $76,966,000. Finally, Deutsche Bank AG purchased a new position in shares of Savara in the 2nd quarter valued at about $5,328,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Savara Company Profile
(
Get Free Report)
Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara's lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.